|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Beyond the surface: Tackling complex dry eye cases
2
Q&A: Anat Loewenstein discusses the use of home OCT
3
Seborrheic dermatitis linked to multiple epithelial barrier diseases
4
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
5














































.png)


